Effects of thyroid disorders on the bone;Auswirkungen von schilddrüsenfehlfunktionen auf den knochen

Wiener Medizinische Wochenschrift

Volumn 155, Issue 19-20, 2005, Pages 444-453

  Mikosch, Peter ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Bone metabolism; Bone mineral density; Fractures; Hyperthyroidism; Hypothyroidism; L thyroxine; Osteoporosis

Indexed keywords

ANTITHYROID AGENT; LEVOTHYROXINE; THYROID HORMONE;

BONE CELL; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CELL MATURATION; DEVELOPMENT; HUMAN; HYPERTHYROIDISM; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PREGNANCY; PREMENOPAUSE; REVIEW; SKELETON; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND;

ADOLESCENT; ADULT; AGED; ANTITHYROID AGENTS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CHILD; CHILD, PRESCHOOL; CLIMACTERIC; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; PREGNANCY; THYROID FUNCTION TESTS; THYROID HORMONES; THYROXINE;

EID: 28044469536     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-005-0222-0     Document Type: Review

References (88)

1. Schindler AE (2003) Thyroid function and post-menopause. Gynecol Endocrinol 17: 79-85
2. Von Recklinghausen FD (1891) Die fibröse oder deformierende Ostitis, die Osteomalazie und die osteoplastische Carzinose in ihren gegenseitigen Beziehungen. Festschrift Rudolf Virchow, George Reimer, Berlin, pp 1-89
3. Plummer WA (1928) Cases showing osteoporosis due to decalcification in exophtalmic goiter. Staff Meet Mayo Clin 3: 119-121
4. Anonymous (2001) Osteoporosis, prevention, diagnosis and therapy. JAMA 285: 785-795
5. Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240: 889-895
6. Rizzoli R, Poser J, Bürgi U (1986) Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 35: 71-74
7. LeBron BA, Pekary AE, Mirell C, Hahn TJ, Hershman JM (1989) Thyroid hormone 5′deiodinase activity, nuclear binding, effects of mitogenesis in UMR-106 osteoblastic osteosarcoma cells. J Bone Miner Res 4: 173-178
8. Kasono K, Sato K, Han DC, Fujii Y, Tsushima T, Shizume K (1988) Stimulation of alkaline phosphatase activity by thyroid hormone in mouse osteoblast-like cells (MCT3T): a possible mechanism of hyperalkaline phosphatasia in hyperthyroidism. J Bone Miner Res 4: 355-363
9. Kassem M, Mosekilde L, Eriksen EF (1993) Effects of tri-iodothyronine on DNA synthesis and differentiation markers of normal human osteoblast-like cells. Biochem Mol Biol Int 30: 779-78
10. Lakotos P, Stern PH (1991) Evidence for direct non-genomic effects of triiodothyronine on bone rudiments in rats: stimulation of the inositole phosphatase second messenger system. Acta Endocrinol (Copenh) 125: 603-608
11. Schmid C, Schlapfer I, Futo E, Waldvogel M, Schwander J, Zapf J, Frosch ER (1992) Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro. Acta Endocrinol (Copenh) 126: 467-473
12. Lakotos P, Caplice MD, Khanna V, Stern PH (1993) Thyroid hormones increase insulin-like growth factor I content in the medium of rat bone tissue. J Bone Miner Res 8: 1475-1481
13. Huank BK, Golden LA, Tarjan G, Madison LD, Stern PH (2000) Insulin-like growth factor I production is essential for anabolic effects of thyroid hormone in osteoblasts. J Bone Miner Res 15: 188-197
14. Williams GR, Bland R, Sheppard MC (1995) Retinoids modify regulation of endogenous gene expression by vitamin D3 and thyroid hormone in three osteosarcoma cell lines. Endocrinology 136: 4304-4314
15. Glantschnig H, Varga F, Klaushofer K (1996) Thyroid hormone and retinoic acid induce the synthesis of insuline-like growth factor-binding protein-4 in mouse osteoblastic cells. Endocrinology 137: 281-286
16. Abu EO, Bord S, Horner A, Chatterjee VK, Compston JE (1997) The expression of thyroid hormone receptors in human bone. Bone 21: 137-142
17. Allain TJ, Yen PM, Flanagan AM, McGregor AM (1996) The isoform-specific expression of the tri-iodothyronine receptor in osteoblasts and osteoclasts. Eur J Clin Invest 26: 418-425
18. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodelling. Cell 115: 151-162
19. Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE (2002) Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86: 642-650
20. Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K (2004) Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol 201: 17-25
21. Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y (2005) Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 152: 347-353
22. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella S (2004) High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 25: 785-791
23. Maziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C (2005) Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen an bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for different thyroid carcinoma. J Bone Miner Res 20: 480-486
24. Dimai HP, Piswanger-Sölkner C, Fahrleitner A, Ramschak-Schwarzer S, Wenisch H, Gugatschka M, Obermayer-Pietsch B, Leb G (2005) Another hormonal upstream factor in the OPG/RANK-L system? Effects of the thyroid stimulating hormone TSH on bone metabolism. Osteoporosis Int (Suppl 1) 15: S16-17
25. Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P (2005) Serum Levels of RANKL and OPG in Men with Differentiated Thyroid Cancer on Suppressive L-Thyroxine Treatment. Thyroid (submitted)
26. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of nontraumatic fracture. JAMA 291: 1108-1113
27. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19: 235-244
28. Thorngren KG, Hansson LI (1973) Effect of thyroxine and growth hormone on longitudinal bone growth in the hypophysectomized rat. Acta Endocrinol (Copenh) 74: 24
29. Draznin B, Burstein PJ, Heinrich UE, Johnson CB, Emler CA, Schalen DS (1980) Insulin-like growth factor and its carrier protein in hypopituitary and hypothyroid children and adults. Clin Endocrinol (Oxf) 12: 137-142
30. Eriksen EF, Mosekilde L, Melsen F (1986) Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodelling cycle. Bone 7: 101-108
31. Mikosch P, Jauk B, Gallowitsch HJ, Pipam W, Kresnik E, Lind P (2001) Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. Thyroid 11: 257-263
32. Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kränzlin M (2004) Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomised controlled trial. Osteoporosis Int 15: 209-216
33. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B (1991) Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine Ann Intern Med 113: 265-269
34. Saggese G, Bertelloni S, Baroncelli GI, Costa S, Ceccarelli C (1996) Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study. Eur J Pediatr 155: 452-457
35. Leger J, Ruiz JC, Guibourdenche J, Kindermans C, Garabedian M, Czernichow P (1997) Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Pädiatr 86: 704-710
36. Ross DS (1993) Bone density is not reduced during the short-term administration of levothyroxine to post-menopausal women with subclinical hypothyroidism: A randomized prospective study. Am J Med 95: 385-388
37. Castro JH, Genuth SM, Klein L (1975) Comparative response to parathyroid hormone in hyperthyroidism and hypothyroidism. Metabolism 24: 839-848
38. Bouillon R, Muls E, De Moor P (1980) Influence of thyroid function on the serum concentration of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 51: 793-797
39. Lekkerkerker JFF, Doorenbos H (1973) The influence of thyroid hormone on calcium absorption from the gut in relation to urinary calcium excretion. Acta Endocrinol (Copenh) 73: 672-680
40. Farnsworth AE, Dobyns BM (1974) Hypercalcemia and thyrotoxicosis. Med J Aust 2: 782-784
41. Baxter JD, Bondy PK (1966) Hypocalcaemia and thyrotoxicosis. Ann Int Med 65: 429-442
42. MacMeod JM, Mchardy KC, Harvey RD, Duncan A, Reid IW, Bewsher PD, Robins SP (1993) The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol 38: 49-53
43. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD (1994) Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78: 955-959
44. Meunier PJ, Bianchi GCS, Edouard CM, Bernard JC, Coupron P, Vignon GE (1972) Bone manifestations of thyrotoxicosis. Orthopedic Clin North Am 3: 745-774
45. Mosekilde L, Melson F (1978) Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. II Bone histomorphometry. Acta Endocrinol 87: 751-758
46. Fraser SA, Smith DA, Anderson JB, Wilson GM (1971) Osteoporosis and fractures following thyrotoxicosis. Lancet 1: 981-983
47. Mikosch P (2004) Die Knochenszintigraphie in der Diagnostik metabolischer Knochenerkrankungen. Wien Med Wochenschr 154: 119-126
48. Lucidarme N, Ruiz JC, Czernichow P, Leger J (2000) Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease. J Patiatr 137: 56-62
49. Radetti G, Bona G, Corrias A, Cappa M, DeSanctis V, Lauriola S, Paganini C, Rigon F (2002) Does Graves' disease during puberty influence adult bone mineral density? Horm Res 58: 176-179
50. Oikawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, Ogihara H, Ishigaki J, Inoue T (1999) Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol 50: 171-176
51. Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J clin Endocrinol Metab 85: 1099-1106
52. Obermayer-Pietsch B, Dobnig H, Warnkross H, Dimai HP, Weber K, Berghold A, Leb G (2000) Variable bone mass recovery in hyperthyroid bone disease after radio-iodine therapy in postmenopausal patients. Maturitas 35: 159-166
53. Faber J, Galløe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 130: 350-356
54. Krolner B, Jorgensen JV, Nielsen SP (1983) Spine bone mineral content in myxoedema and thyrotoxicosis: effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol 18: 439-446
55. Ribot C, Tremollieres F, Fouilles JM, Louvet JP (1990) Bone mineral density and thyroid hormone therapy. Clin Endocrinol 33: 143-153
56. Diamond T, Nery L, Hales I (1991) A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72: 1184-1188
57. Földes J, Tarjan G, Szathmari M, Varga F, Krasznai I, Horvath CS (1993) Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis. Clin Endocrinol 39: 521-527
58. Franklyn JA, Betteridge J, Daykin J, Sheppard MC (1993) Osteoporosis secondary to thyroid disorders. J Endocrinol 137: S37
59. Schneider DL, Barrett-Connor EL, Morton DJ (1994) Thyroid hormone use and bone mineral density in elderly women. Effect of estrogen. JAMA 271: 1245-1249
60. Greenspan SL, Greenspan FS, Resnick NM, Block JE, Freidlander AL, Genant HK (1991) Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med 91: 5-14
61. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY (1996) Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81: 4278-4289
62. Greenspan SL, Greenspan FS (1999) The effect of thyroid hormone on skeletal integrity. Ann Intern Med 130: 750-758
63. Müller CG, Bayley TA, Harrison JE, Tsang R (1995) Possible limited loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 5: 81-87
64. Görres G, Kaim A, Otte A, Götze M, Müller-Brand J (1996) Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. Eur J Nucl Med 23: 690-692
65. Kvetny J (2005) Subclinical hyperthyroidism in patients with nodular goiter represents a hypermetabolic state. Exp Clin Endocrinol Diabetes 113: 122-126
66. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM (2001) A randomised trial comparing levothyroxine with radioactive iodine in the treatment of sporadic non-toxic goiter. J Clin Endocrinol Metab 86: 998-1005
67. Mikosch P, Obermayer-Pietsch B, Jost R, Jauk B, Gallowitsch HJ, Kresnik E, Leb G, Lind P (2003) Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. Thyroid 13: 347-355
68. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78: 818-823
69. Toivonen J, Tähtelä R, Laitinen K, Risteli J, Välimäki MJ (1998) Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138: 667-673
70. Florkowski CM, Brownlie BE, Elliot JR, Ayling EM, Turner JG (1993) Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. N Z Med J 106: 443-444
71. Guo CY, Weetman AP, Eastell R (1997) Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 46: 301-307
72. Solomon BL, Wartofsky L, Burmann KD (1993) Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 3: 17-23
73. Wejda B, Hintze G, Katschinski B, Olbricht TH, Benker G (1995) Hip fractures and the thyroid: a case-control study. J Intern Med 237: 241-247
74. Bauer DC, Cummings SR, Tao JL, Browner WS (1992) Hyperthyroidism increases the risk of osteoporotic hip fractures. A prospective study. Am Soc Bone Miner Res 7: S 121 (Abstract 116)
75. Bauer DC, Ettiger B, Nevitt MC, Stone KL (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134: 561-568
76. Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism. A nationwide follow-up study in 16,249 patients. Thyroid 12: 411-419
77. Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk - a meta analysis. Thyroid 13: 585-593
78. Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender-specific aspects. Wien Med Wochenschr 154: 411-415
79. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubhahn DB, Korach KS (1994) Estrogen resistance caused by a mutagen in the estrogen-receptor gene in men. N Engl J Med 331: 1056-1061
80. Khosla S, Melton LJ III, Riggs BL (2001) Estrogens and bone health in men. Calcif Tissue Int 69: 189-192
81. Marcocci C, Golia F, Vignali E, Pinchera A (1997) Skeletal integrity in men chronically treated with suppressive doses of thyroxine. J Bone Miner Res 12: 72-77
82. Jodar E, Martinez-Diaz-Guerra G, Azriel S, Hawkins F (2001) Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease. Calcif Tissue Int 69: 84-87
83. Baran DT (1994) Detrimental skeletal effects of thyrotropin suppressive doses of thyroxine: fact or fantasy? J Clin Endocrinol Metab 78: 816-817
84. Baran DT (1994). Thyroid hormone and bone mass: the clinician's dilemma. Thyroid 4: 143-144
85. Bartalena L, Martino E, Pacchiarotti A, Grasso L, Aghini-Lombardi F, Buratti L, Bambini G, Breccia M, Pinchera A (1987) Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 64: 849
86. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T, Holick M, Greenspan SL (1993) Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 77: 664-669
87. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greespan SL (1998) Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 83: 2324-2330
88. Scharla SH, Wolf S, Dull R, Lempert UG (1999) Prevalence of low bone mass and endocrine disorders in hip fracture patients in Southern Germany. Exp Endocrinol Diabetes 107: 547-554